Tumours of kidneys, urinary bladder and prostate in obesity and diabetes

Czech version

Authors: Š. Svačina
Authors‘ workplace: III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in: Vnitř Lék 2008; 54(5): 464-467
Category:

Overview

Relations of obesity and type 2 diabetes to urinary tract cancer were described. Occurrence of kidney cancer is more often in both obesity and type 2 diabetes. Bladder cancer has no relation to obesity but is more common in type 2 diabetic patients. Inverted relations were found in prostatic cancer. This disease is more common in obese patents but less common in type 2 diabetes. Diabetics are partly protected to this disease. Physical activity decreases the risk of kidney and bladder cancer but has no relation to bladder cancer. Urinary tract cancers have no relation to type 1 diabetes. We have found 3.9 time higher risk of kidney cancer in Czech diabetic patients.

Key words:
metabolic syndrome - diabetes mellitus type 2 - urinary tract cancer - physical activity

Sources

1. Beebe-Dimmer JL, Dunn RL, Sarma AV et al. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007; 109: 875-881.

2. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638.

3. Calton BA, Chang SC, Wright ME et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 2007; 18: 493-503.

4. Demark-Wahnefried W, Moyad MA. Dietary intervention in the management of prostate cancer. Curr Opin Urol 2007; 17: 168-174.

5. Garfinkel L. Overweight and cancer. Ann Intern Med 1985; 103: 1034-1036.

6. Hjalgrim H, Frisch M, Ekbom A et al. Cancer and diabetes - a follow-up study of two population-based cohorts of diabetic patients. J Intern Med 1997; 241: 471-475.

7. Holick CN, Giovannucci EL, Stampfer MJ et al. Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women. Int J Cancer 2007; 120: 140-146.

8. Larsson SC, Orsini N, Brismar K et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49: 2819-2823.

9. Lin AM, Small EJ. Prostate cancer update: 2006. Curr Opin Oncol 2007; 19: 229-233.

10. Lindblad P, Chow WH, Chan J et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 1999; 42: 107-112.

11. Lund Håheim L, Wisløff TF, Holme I et al. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006; 164: 769-774.

12. Matoulek M, Svačina Š, Topolčan O et al. Metabolický syndrom a nádory. In: Perušičová J (ed). Diabetes mellitus - léčba a komplikace. Symposium 6. Praha: Galén 2001: 84-88.

13. Moyad MA. Obesity, interrelated mechanisms, and exposures and kidney cancer. Semin Urol Oncol 2001; 19: 270-279.

14. Nakata S, Sato J, Ohtake N et al. Epidemiological study of risk factors for bladder cancer. Hinyokika Kiyo 1995; 41: 969-977.

15. O'Malley RL, Taneja SS. Obesity and prostate cancer. Can J Urol 2006; 13(Suppl 2): 11-14.

16. Pan SY, DesMeules M, Morrison H et al. Canadian Cancer Registries Epidemiology Research Group Obesity, high energy intake, lack of physical activity, and the risk of kidney cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2453-2460.

17. Platz EA, Leitzmann MF, Visvanathan K et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819-1825.

18. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578.

19. Schiel R, Beltschikow W, Steiner T et al. Diabetes, insulin, and risk of cancer. Methods Find Exp Clin Pharmacol 2006; 28: 169-175.

20. Spyridopoulos TN, Petridou ET, Skalkidou A et al. Obesity and Cancer Oncology Group. Low adiponectin levels are associated with renal cell carcinoma: a case-control study. Int J Cancer 2007; 120: 1573-1578.

21. Stevens VL, McCullough ML, Diver WR et al. Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control 2005; 16: 643-650.

22. Strickler HD, Wylie-Rosett J, Rohan T et al. The relation of type 2 diabetes and cancer. Diabetes Technol Ther 2001; 3: 263-274.

23. Svačina Š, Matoulek M, Svobodová S et al. Nádory trávicího traktu a diabetes. Vnitř Lék 2004; 50: 386-391.

24. Svačina Š et al. Metabolický syndrom. Praha: Triton 2006.

25. Vainio H, Kaaks R, Bianchini F. Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev 2002; 11: S94-S100.

26. Velicer CM Dublin S, White E. Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications. Prostate Cancer Prostatic Dis 2007; 10: 46-51.